Early clinical data with HER2-CAR VSTs in glioblastoma show feasibility, safety, and evidence of clinical benefit, and CMV-specific CAR-T platforms are being explored for vaccine-mediated in vivo boosting [99,102,103]. Here, ERBB2 is linked to glioblastoma.